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Introduction
DNA 5-methylcytosine (5-mC) modifications 
are increasingly recognized as a key process 
in the pathogenesis of complex disorders, 
including cancer, diabetes, and cardio vascular 
disease (Feinberg 2010; Ordovas and Smith 
2010). Several recent studies have investigated 
epigenetic functions of 5-hydroxymethyl-
cytosine (5-hmC), a hydroxylated and 
methylated form of cytosine. The conver-
sion of 5-mC to 5-hmC is a step prior to 
demethylation (Shen et al. 2013; Song et al. 
2013) and seems to play a direct role in the 
regulation of gene expression (Branco et al. 
2012). Although 5-hmC is able to bind to 
DNA methylation binding domain (MBD) 3 
(Baubec et al. 2013), it reduces the binding of 
other MBD proteins to methylated DNA and 
prevents DNA methyltransferase (DNMT)-
mediated methylation of the target cytosine 
(Tahiliani et al. 2009). Several studies have 
evaluated blood cell global DNA methyla-
tion and its determinants in population-based 
studies (reviewed by Terry et al. 2011). 
However, few human studies have evaluated 
global DNA hydroxy methylation. Specifically, 
the association between human blood cell 
global DNA methylation and global DNA 
hydroxymethylation has not been previously 
evaluated in epidemiologic studies.
Environmental exposures, such as to 
arsenic or cadmium, can disrupt gene expres-
sion (Andrew et al. 2008; Bourdonnay et al. 
2009; Castillo et al. 2012; Cheng et al. 2012; 
Hossain et al. 2012; Su et al. 2006). Findings 
suggest that the health effects of environ mental 
exposures, including exposure to metals, could 
be mediated in part by epigenetic mechanisms 
(Arita and Costa 2009; Reichard and Puga 
2010; Ren et al. 2011; Smeester et al. 2011). 
Results of studies conducted in vitro and in 
primary human tissue samples also support 
that metals can have epigenetic effects (Huang 
et al. 2008; Kile et al. 2012; Lambrou et al. 
2012; Smeester et al. 2011). No studies have 
evaluated environmental determinants of 
global DNA hydroxy methylation, including 
exposure to metals.
In this study, we examined the association 
between global DNA methylation and global 
DNA hydroxymethylation in a subsample 
of Strong Heart Study (SHS) participants 
who had metals measured in urine and also 
had buffy coat and blood available for DNA 
isolation (Lee et al. 1990; Scheer et al. 2012). 
In addition, we explored the association of 
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Background: The association between human blood DNA global methylation and global hydroxy­
methylation has not been evaluated in population­based studies. No studies have evaluated environ­
mental determinants of global DNA hydroxymethylation, including exposure to metals.
oBjective: We evaluated the association between global DNA methylation and global DNA hydroxy­
methylation in 48 Strong Heart Study participants for which selected metals had been measured in 
urine at baseline and DNA was available from 1989–1991 (visit 1) and 1998–1999 (visit 3). 
Methods: We measured the percentage of 5­methylcytosine (5­mC) and 5­hydroxy methylcytosine 
(5­hmC) in samples using capture and detection antibodies followed by colorimetric quantification. 
We explored the association of participant characteristics (i.e., age, adiposity, smoking, and metal 
exposure) with both global DNA methylation and global DNA hydroxy methylation.
results: The Spearman’s correlation coefficient for 5­mC and 5­hmC levels was 0.32 (p = 0.03) 
at visit 1 and 0.54 (p < 0.001) at visit 3. Trends for both epigenetic modifica tions were consistent 
across potential determinants. In cross­sectional analyses, the odds ratios of methylated and hydroxy­
methylated DNA were 1.56 (95% CI: 0.95, 2.57) and 1.76 (95% CI: 1.07, 2.88), respectively, 
for the comparison of participants above and below the median percentage of dimethyl arsinate. 
The corresponding odds ratios were 1.64 (95% CI: 1.02, 2.65) and 1.16 (95% CI: 0.70, 1.94), 
respectively, for the comparison of participants above and below the median cadmium level. Arsenic 
exposure and metabolism were consistently associated with both epigenetic markers in cross­sectional 
and prospective analyses. The positive correlation of 5­mC and 5­hmC levels was confirmed in an 
independent study population.
conclusions: Our findings support that both epigenetic measures are related at the population 
level. The consistent trends in the associations between these two epigenetic modifications and the 
charac teristics evaluated, especially arsenic exposure and metabolism, suggest the need for under­
standing which of the two measures is a better biomarker for environmental epigenetic effects in 
future large­scale epidemiologic studies.
citation: Tellez­Plaza M, Tang WY, Shang Y, Umans JG, Francesconi KA, Goessler W, 
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participant charac teristics (age, sex, education, 
adiposity, smoking, alcohol intake, metal 
exposure, and arsenic metabolism) with both 
global DNA methylation and global DNA 
hydroxy methylation. We had no a priori 
hypothesis on the direction of the associations 
under study.
Methods
Study population. The SHS is a population-
based cohort study funded by the U.S. 
National Heart, Lung, and Blood Institute 
that recruited 4,549 participants from 
Arizona, Oklahoma, and North and South 
Dakota in 1989–1991 (overall response rate 
62%) (Lee et al. 1990). Starting in 1998, an 
ancillary study to the SHS, the Strong Heart 
Family Study (SHFS) recruited extended 
family members of the original SHS partici-
pants who were ≥ 18 years of age to evaluate 
genetic determinants of cardio metabolic 
disease in American Indian populations 
(North et al. 2003). For the present study, 
the population was restricted to SHS partici-
pants with measurements of metals in urine 
at baseline (visit 1) (Scheer et al. 2012) who 
also participated in the SHFS (North et al. 
2003) and had biological samples collected 
at two follow-up clinic visits conducted in 
1993–1995 (visit 2) and 1997–1999 (visit 3). 
A total of 517 partici pants met those criteria. 
To maximize the efficiency of this relatively 
small epigenetic study (Stuart and Hanna 
2013; Zubizarreta et al. 2013), we used a 
strati fied random sample to select 8 partici-
pants with moderate arsenic exposure and 
8 participants with low arsenic exposure 
from each region (16 from Arizona, 16 from 
Oklahoma, and 16 from North or South 
Dakota), resulting in a total of 48 partici pants. 
On the basis of SHS distributions in 1989–
1991, we defined relatively low and moderate 
arsenic exposures of the sum of inorganic and 
methylated arsenic species as urinary concen-
trations < 7.2 μg/g (tertile 1) and ≥ 14.0 μg/g 
(tertile 3), respectively. The protocol for this 
ancillary study was approved by the Johns 
Hopkins Bloomberg School of Public Health 
Institutional Review Board and the Indian 
Health Service Review Boards and by the 
participating American Indian communities. 
All the participants provided oral and written 
informed consent.
Epigenetic measurements. We detected 
global methyla tion and global hydroxy-
methylation in DNA isolated from frozen 
buffy coat from visit 1 and frozen whole blood 
from visit 3 using Methylamp (currently 
known as MethylFlash) Methylated and 
Hydroxymethylated DNA Quantification Kits 
(Epigentek) according to the manufacturer’s 
instructions. In brief, 5-mC and 5-hmC 
were separately detected using an ELISA-like 
reaction. Levels of 5-mC or 5-hmC in DNA 
of all biologi cal samples are reported as the 
amount of methylated or hydroxy methylated 
cystosines relative to the cytosine genomic 
content (percent). For the global DNA 
methyla tion assay, the capture antibody for 
5-mC had no or negligible cross-reactivity to 
5-hmC and unmethylated cytosine. Global 
DNA hydroxy methylation was quantified by 
specifically measuring levels of 5-hmC without 
cross-reactivity to 5-mC and unmethylated 
cytosine. The input DNA concentrations for 
the 5-mC and 5-hmC assays were 100 ng and 
37.5 ng, respectively. All samples (or repeats) 
were loaded using the same amount of DNA 
in the assay plate.
All samples and methylated/hydroxy-
methylated standards were measured in 
triplicate, and the average is reported. The 
observed quality control data were excellent 
[median (interquartile range; IQR) intra-assay 
coefficient of variation (CV) ranged from 
0.25% (0.10, 0.51) to 0.3% (0.20, 0.69); 
intraclass correlation coefficient (ICC) > 0.998; 
see Supplemental Material, Table S1], indi-
cating that the variability of the determina-
tions could be almost completely attributed 
to between-subjects variation. Leukocyte 
composition of peripheral blood can covary 
with patterns of DNA methylation and also 
with participant characteristics, such as sex or 
age (Lam et al. 2012). Thus, it was impor-
tant to account for blood cell hetero geneity 
in the statistical analysis of DNA methyla-
tion and hydroxymethylation data. Blood cell 
count data, however, was available only for 
the blood samples corresponding to the DNA 
extracted in visit 3. Cell counts were avail-
able for the following subtypes: neutrophils, 
lymphocytes, monocytes, eosinophils, and 
basophils (see distribution in Supplemental 
Material, Table S2).
Other variables. Participants were inter-
viewed and physically examined by centrally 
trained and certified staff following a standard 
protocol (Lee et al. 1990). Baseline informa-
tion on socio demographic data (age, sex, 
education), smoking status (never/former/
current), cumulative smoking (cigarette 
pack-years), and alcohol use (never/former/
current) were obtained by questionnaire 
during the interview. Measures of adiposity 
obtained during the physical exam included 
body mass index (BMI; kilograms per meter 
squared), percent body fat estimated by 
bioelectric impedance (Impedance Meter, 
model B1A101; RJL Equipment Company), 
and waist circumference measured supine in 
centimeters.
Spot urine samples were frozen without 
chemical additives within 1–2 hr of collection 
at baseline (visit 1) (Bornhorst et al. 2005). 
In 2009, urine samples were thawed, and 
arsenic, cadmium, antimony, and tungsten 
were measured using inductively coupled 
plasma-mass spectrometry (ICPMS), as 
previously described by Scheer et al. (2012). 
Arsenic species [inorganic arsenic (iAs; 
arsenite, arsenate), methyl arsonate (MMA), 
and dimethyl arsinate (DMA)] were measured 
in the same urine samples using anion-
exchange high-performance liquid chroma-
tography coupled with ICPMS. The limits of 
detection were 0.1 μg/L for total arsenic and 
arsenic species, and 0.05 μg/L for cadmium, 
antimony, and tungsten. None of the samples 
included in this study were below the limit of 
detection. The inter assay CVs for total arsenic, 
arsenite, arsenate, MMA, DMA, cadmium, 
antimony, and tungsten were 4.4, 14.7, 6.9, 
6.4, 6.0, 8.7, 30.0, and 14.5%, respectively. 
For every batch of 79 samples, 10 of the 
samples were analyzed in duplicate. The mean 
intra-assay CVs for total arsenic, arsenite, 
arsenate, MMA, DMA, cadmium, antimony, 
and tungsten were 1.53, 4.46, 4.23, 3.02, 
1.49, 1.34, 3.29, and 0.57%, respectively. The 
estimated intra-assay ICCs in these samples 
for total arsenic, arsenite, arsenate, MMA, 
DMA, cadmium, antimony, and tungsten 
were 0.997, 0.990, 0.996, 0.992, 0.987, 0.994, 
0.966, and 0.990, respectively. To account for 
urine dilution, urinary metal concentrations 
(micrograms per liter) were divided by urinary 
creatinine concentrations (grams per liter) and 
reported in micro grams per gram creatinine. 
The Spearman’s correlation coefficients (rs) for 
metal-by-metal levels ranged from 0.07 for the 
correlation between antimony and arsenic to 
0.43 for the correlation between tungsten and 
antimony. To assess arsenic metabo lism, we 
computed the percent iAs (%iAs), %MMA, 
and %DMA by dividing the concentration of 
each of them by the sum of the inorganic and 
methylated species.
Statistical analyses. We estimated median 
(IQR) of %5-mC and %5-hmC levels by 
participant characteristics. The levels of 
%5-mC and %5-hmC were not normally 
distributed and were thus logit-transformed for 
statistical analyses. Scatter plots, lowess models, 
and rs were used to descriptively display the 
association between global DNA methyla-
tion and global DNA hydroxy methylation at 
visits 1 and 3. We also examined crude linear 
trends in the association of global DNA 
methyla tion and global DNA hydroxy-
methylation with continuous variables, 
including age, BMI, percent body fat, waist 
circumference, urinary metal concentrations 
(arsenic, cadmium, tungsten, and antimony), 
and arsenic metabolic profile (%iAs, %MMA, 
and %DMA); the corresponding linear 
correlation coefficients were estimated as the 
square root of the R2 of the under lying simple 
linear regression models. In addition, we used 
linear regression models on logit-transformed 
measures of global DNA methylation and 
global DNA hydroxy methylation to examine 
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associations between methylation and hydroxy-
methylation levels and categorical variables 
[sex, education (< 12 years/≥ 12 years), 
smoking status (ever/never), alcohol status 
(ever/never), BMI (< 30 kg/m2/≥ 30 kg/m2)], 
and continuous variables dichotomized at their 
corresponding medians (waist circumference, 
percent body fat, urinary arsenic concentration 
and metabolism, and urinary concentrations of 
cadmium, antimony, and tungsten). 
Because of limited sample size and difficul-
ties in conducting longitudinal evaluations of 
changes over time, we performed the analysis 
separately for visits 1 and 3; results from parsi-
monious models with no multi variable adjust-
ment were considered the main results. We 
examined the association of baseline urinary 
metal concentrations with baseline global 
DNA methylation and global DNA hydroxy-
methyla tion to evaluate the hypothesis that 
metals are cross-sectionally associated with 
DNA methylation and hydroxy methyla tion 
levels. To evaluate the hypothe sis that metals 
are prospectively related to DNA methylation 
and hydroxymethylation levels, we examined 
the association of baseline metal exposure 
biomarkers with visit 3 global DNA methyla-
tion and global DNA hydroxy methyla tion. 
For arsenic, under constant conditions of 
exposure over time, urinary concentrations 
and metabolism biomarkers have been fairly 
constant, as previously shown in our study 
population (Navas-Acien et al. 2009) and in 
previous studies measuring arsenic in private 
and public drinking water systems over long 
periods of time (Karagas et al. 2001; Ryan 
et al. 2000; Steinmaus et al. 2005). Given 
this background, evaluating the association 
of arsenic exposure and metabolism with 
epi genetic measures in visits 1 and 3 allowed 
us to evaluate the consistency of the associa-
tions assuming constant arsenic exposure and 
metabolic processes.
In addition to crude regression models 
(model 1), we also conducted multi variable 
regression models adjusting for age (years), 
sex (male, female), BMI (continuous), and 
smoking status (never, former, and current 
smokers). To evaluate a potential effect of 
blood cell type hetero geneity in the associa-
tions by participant charac teristic, we also 
adjusted visit 3 models for cell type hetero-
geneity (models 2 and 3). We had available 
information on white blood cell count and 
percent cell type only for visit 3. Because the 
power in our study is limited and because 
neutrophils are the cell type more common 
in blood, we present only results for models 
adjusted for log-transformed total cell count 
and percentage of neutrophils. In additional 
sensitivity analyses, we adjusted for log-
transformed total cell count and cell counts 
of neutrophils, basophils, monocytes, and 
lymphocytes, with similar findings (data 
not shown). All statistical analyses were 
conducted using R software (version R3.1.0; 
http://www.r-project.org/). 
Post hoc analysis. The SHS population has 
high rates of cardio vascular disease. To evaluate 
5-mC and 5-hmC levels in a population with 
a low burden of disease, we detected global 
methylation and global hydroxy methylation 
in DNA isolated from frozen whole blood 
samples from 48 healthy men from Spain 
(24 were never-smokers and 14 were obese) 
who participated in the Aragon Workers 
Health Study (AWHS). The AWHS is a large 
prospective cohort study that aims to charac-
terize the factors associated with metabolic 
abnormalities and sub clinical athero sclerosis in 
a middle-aged population free of cardio vascular 
disease (Casasnovas et al. 2012). The AWHS 
design and baseline charac teristics have been 
reported elsewhere (Casasnovas et al. 2012). 
To measure 5-mC and 5-hmC in the AWHS, 
we used an ELISA method (5-mC and 5-hmC 
kits; Zymo Research) following the manu-
facturer’s instructions; we confirmed that the 
results were consistent in a subsample of the 
SHS with duplicate determinations (data not 
shown). Levels of 5-mC or 5-hmC in DNA 
were measured as the percentage of methylated 
or hydroxymethylated cystosines in total DNA 
content (%5-mC and %5-hmC). The input 
DNA for 5-mC and 5-hmC assays was 50 ng, 
and all samples (or repeats) were loaded with 
the same amount of DNA in the assay plate. 
The intra-assay CVs (IQRs) and ICCs were 
3.14% (3.05, 3.20) and 0.86 for %5-mC, and 
2.80% (1.40, 4.30) and 0.61 for %5-hmC (see 
Supplemental Material, Table S1). 
Results
The mean (± SD) age of the study sample 
was 54.9 ± 7.2 years, 68.7% were women, 
and 58.3% were ever-smokers (Table 1). 
The study population was representative of 
the SHS participants who also participated 
in the SHFS (Table 1). The overall median 
(IQR) levels of global DNA methylation and 
global DNA hydroxy methylation were 0.32% 
(0.15, 0.58) and 0.12% (0.07, 0.17), respec-
tively, for visit 1 and 0.32% (0.13, 0.55) and 
0.15% (0.09, 0.25), respectively, for visit 3 
(see Supplemental Material, Table S3). For 
5-mC and 5-hmC levels, rs = 0.32 (p = 0.03) 
at visit 1 and rs = 0.54 (p < 0.001) at visit 3 
(Figure 1). 
The direction of estimated linear trends in 
5-mC and 5-hmC levels by levels of possible 
determinants was generally consistent for both 
epigenetic modification measures and at both 
visits (see Supplemental Material, Figures S1 
and S2), with some exceptions. In crude cross-
sectional analyses, baseline age, %iAs, and 
%MMA showed a trend toward an inverse 
association with 5-mC and 5-hmC measured 
in visit 1 (Table 2; see also Supplemental 
Material, Figures S1 and S2). Baseline 
adiposity measures (especially BMI), %DMA, 
cadmium, antimony, and tungsten showed a 
trend toward a positive association with 5-mC 
and 5-hmC measured in visit 1 (Table 2; 
see also Supplemental Material, Figures S1 
and S2). Arsenic metabo lism markers (%iAs, 
%MMA, and %DMA) showed similar direc-
tion and magnitude for the cross-sectional 
and prospective associations with %5-mC 
and %5-hmC levels (Tables 2 and 3; see also 
Supplemental Material, Figures S1 and S2). 
In a comparison of participants with baseline 
%DMA above and below 78.3%, the odds 
ratios (ORs) of %5-hmC were 1.75 [95% 
confidence interval (CI): 1.07, 2.88] at visit 1 
and 1.34 (95% CI: 0.79, 2.26) at visit 3 
(Table 3). Comparing participants with 
urinary cadmium concentrations above and 
below 0.87 μg/g resulted in an OR for %5-mC 
of 1.64 (95% CI: 1.02, 2.65) at visit 1 but 
0.86 (95% CI: 0.47, 1.56) at visit 3 (Table 3). 
Table 1. Baseline participant characteristics in the Strong Heart Study (SHS).
Characteristic
SHS sample, visit 1 
(n = 48)
SHS and SHFSa 
(n = 517)
Age (years) 54.9 ± 7.2 55.0 ± 7.3
Female 33 (68.7) 343 (66.3)
Education < high school 19 (39.6) 214 (41.4)
BMI (kg/m2)b 31.0 ± 5.8 31.6 ± 6.0
Waist circumference (cm)c 105.0 ± 14.0 106.7 ±14.3
Percent body fat 36.8 ± 8.8 37.9 ± 8.9
Ever-smokers 28 (58.3) 326 (63.1)
Cumulative smoking (pack-years)c 8.5 ± 15.5 9.3 ± 17.40
Ever alcohol drinkers 40 (83.3) 421 (81.4)
Urinary arsenic (μg/g)d 10.02 (6.32, 16.20) 8.10 (5.10, 14.6)
%iAs 8.53 (5.53, 10.71) 7.63 (5.44, 10.30)
%MMA 14.35 (11.02, 17.82) 13.69 (10.60, 16.93)
%DMA 78.32 (71.27, 81.39) 78.69 (72.15, 83.14)
Cadmium (μg/g) 0.88 (0.52, 1.45) 0.92 (0.61, 1.45)
Antimony (μg/g) 0.27 (0.17, 0.46) 0.22 (0.15, 0.36)
Tungsten (μg/g) 0.13 (0.08, 0.27) 0.14 (0.07, 0.25)
NA, not available. Data are mean ± SD, n (%), or median (IQR). 
aSHS participants with urinary metal measurements who also participated in the Strong Heart Family Study (SHFS). 
bn = 47. cn = 46. dSum of inorganic and methylated arsenic species in urine. 
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In general, adjustment for age, sex, BMI, 
and smoking status did not change the direc-
tion of the observed associations. Actually, 
the correlation of %5-mC and %5-hmC 
became stronger after those adjustments 
(Table 2). In sensitivity analyses adjusting 
for cell hetero geneity in the subset of individ-
uals with cell count data available for visit 3 
(n = 44) (Table 3), results were consistent, 
although some additional prospective trends 
became statistically significant. The ORs of 
%5-mC comparing participants with urinary 
arsenic > 14.0 μg/g and < 7.2 μg/g, and with 
urinary antimony above and below 0.27 μg/g, 
were 0.54 (95% CI: 0.30, 0.97) and 1.93 
(95% CI: 1.07, 3.47), respectively. The ORs 
of %5-hmC comparing participants with 
baseline %MMA above and below 14.4% was 
0.58 (95% CI: 0.35, 0.98).
In a post hoc analysis of the AWHS, the 
median %5-mC and %5-hmC levels were 
0.90% and 0.09%, respectively. For %5-mC 
and %5-mC, the correlation rs = 0.16 
(p = 0.29) (see Supplemental Material, 
Figure S3).
Discussion
Global DNA methylation and global DNA 
hydroxymethylation measured in blood were 
moderately and positively associated in this 
sub sample of participants from the SHS. We 
found consistent associations in our study 
population at two time points approximately 
10 years apart, and also in an independent 
study population from Spain with a low 
burden of disease (AWHS); these associations 
support the close relationship between both 
epigenetic measures. Although our sample 
size was limited, we found statistically signifi-
cant associations between urinary cadmium 
concentrations and global DNA methylation 
and between arsenic metabolism (measured 
as %DMA) and global DNA hydroxy-
methylation. The observed associations 
between arsenic metabolism and global DNA 
methylation and DNA hydroxymethylation 
showed consistent patterns across time. This 
study provided the opportunity to evaluate 
the consistency of potential associations and 
direction of the relationship between these 
two measures of epigenetic modification in 
human blood DNA samples.
Methylation at the 5´ position of cytosine 
in DNA plays a role in regulating gene 
expression (Feinberg 2010). In addition to 
DNA methylation, DNA hydroxy methyla-
tion has also been related to changes in 
gene expression (Branco et al. 2012). In 
the mammalian genome, Ten to Eleven 
Translocation (TET) proteins are responsible 
for catalyzing 5-mC oxidation to 5-hmC 
(Branco et al. 2012; Tahiliani et al. 2009). 
Hydroxymethylation at 5´ CpGs via TETs 
has been shown to contribute to gene tran-
scription by influencing DNA demethylation 
(Baubec et al. 2013; Shen et al. 2013; Song 
et al. 2013) and/or recruitment of transcrip-
tion complexes to repress gene transcription 
(Cimmino et al. 2011). Bisulfite conversion, a 
method traditionally used for the enrichment 
of 5-mC, cannot distinguish between 5-mC 
and 5-hmC (Huang et al. 2010). Before the 
develop ment of 5-hmC profiling strategies, 
it was postulated that hyper methylation of 
promoter regions blocks gene expression, 
whereas hypermethylation of gene bodies 
increases gene expression (Jones 2012). 
Recent studies evaluating genome-wide 
5-hmC profiles in mouse and human embry-
onic stem cells and brain cells have observed 
an enrichment of 5-hmC at gene body 
regions, regulatory (promoter) regions, and 
sites with intermediate CpG density (Branco 
et al. 2012). The presence of 5-hmC in 
gene bodies has been consistently associated 
with gene expression (Branco et al. 2012). 
Altogether, the accumulated evidence suggests 
that gene-specific hydroxy methyla tion has 
dual functions in the regulation of gene 
transcription (Branco et al. 2012). Ficz et al. 
(2011) proposed that the balance between 
DNA methylation and DNA hydroxy-
methylation in the genome is involved in the 
balance between cellular pluripotency and 
lineage commitment. The health implications 
of the relationship between DNA methyla-
tion and hydroxymethylation in differenti-
ated tissues, however, are currently unknown. 
Advanced technology that uses massive 
parallel sequencing on profiling degree of 
5-hmC across the genome may help to under-
stand the role of DNA hydroxymethylation.
In our study population, the levels of 
5-hmC were approximately 2.5-fold lower 
than those of 5-mC (see Supplemental 
Material, Table S3). In a study by Figueroa-
Romero et al. (2012), the mean %5-mC and 
%5-hmC in blood samples from 12 healthy 
individuals from the United States, as 
measured by an ELISA method, were 
0.41% and 0.03%, respectively (5-hmC was 
~ 12-fold lower than 5-mC). The CV and 
ICC of the assays were not provided. In the 
AWHS, the ratio of 5-mC and 5-hmC levels 
was intermediate compared with the SHS 
results and with data from Figueroa-Romero 
et al. (2012); in the AWHS, we found that 
the level of 5-mC was about 10 times that 
of 5-hmC (see “Results”). In the SHS data, 
with very low CVs and high ICCs (see 
Supplemental Material, Table S1), the correla-
tion between 5-mC and 5-hmC was statisti-
cally significant at two time points (Figure 1). 
In the AWHS, the replication study sample, 
the correlation between global DNA methyla-
tion and global DNA hydroxymethylation 
was positive, supporting consistency in the 
direction of the association in a human popu-
lation with a different risk profile. The correla-
tion, however, was weaker and not statistically 
significant. Overall, random sampling vari-
ability due to the small sample size and tech-
nical variability/measurement error cannot be 
discarded as the main reason for the discrepan-
cies in global DNA methyla tion and hydroxy-
methylation levels from human blood DNA 
samples in different study populations.
Changes in DNA methylation have been 
related to environmental exposures such as 
metals, air pollution, benzene, bisphenol A, 
diethylstilbestrol, and dioxins in experimental 
and small population-based studies, although 
the exact mechanisms remain unclear (Bailey 
and Fry 2014; Breton and Marutani 2014; 
Hou et al. 2012). In the present study, we 
found consistent trends for both global DNA 
methylation and global hydroxymethylation 
by different determinants. It is possible that 
DNA hydroxymethylation acts as a proxy for 
DNA methylation or vice versa (the more 
DNA methylation, the greater potential for 
DNA hydroxymethyla tion). Indeed, Ficz et al. 
(2011) reported that 5-hmC was reduced in 
Tet1/2 knockdown cells and Np95–/– cells, and 
Figure 1. Relationship of global DNA methylation (%5‑mC) and global DNA hydroxymethylation (%5‑hmC) in 
blood collected in two study visits approximately 10 years apart [Strong Heart Study (SHS)].
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eliminated in Dnmt1–/–/Dnmt3a–/–/Dnmt3b–/– 
triple knockout embryonic stem cells, 
suggesting that most 5-hmC in the genome 
depends on preexisting 5-mC. Alternatively, 
it is also possible that determinants for DNA 
methylation and DNA hydroxy methylation 
are somewhat common. For instance, based 
on in vivo and in vitro experimental findings, 
it has been hypothesized that oxidative stress 
can regulate both DNA methylation and DNA 
hydroxymethylation processes by impairing 
one-carbon (Lee et al. 2009) and citric acid 
metabolism (Chia et al. 2011) pathways, 
respectively. Additional studies with larger 
sample sizes are needed to investigate the corre-
lation between global and gene-specific DNA 
methylation and DNA hydroxy methylation in 
relation to environmental determinants and 
health outcomes.
In our study, we found some support 
for the relationship between some environ-
mental exposures and global DNA methyla-
tion and global DNA hydroxymethylation. 
In particular, we found a change in the level 
of global DNA methylation and hydroxy-
methyla tion associated with metals exposure. 
For antimony and tungsten, we found positive 
cross-sectional associations with global 
DNA methylation and hydroxymethylation, 
although the association with global DNA 
hydroxymethylation was weaker. The prospec-
tive association of antimony and global DNA 
methylation was statistically significant. The 
association of global DNA methylation and 
hydroxymethylation with these metals has not 
previously been evaluated in human studies. 
Very few studies have evaluated the association 
of arsenic and cadmium exposure with global 
DNA methyla tion in humans. Contrary to our 
findings, Hossain et al. (2012) found that low-
level environmental cadmium exposure was 
associated with global DNA hypomethylation, 
as measured in repetitive elements (a proxy 
for global DNA methylation), in women from 
Argentina (n = 202). In a population from 
Spain (n = 892), increasing arsenic toenail 
concentrations were significantly associated 
with decreasing methylation of LINE-1 (long 
interspersed nucleotide element-1) (Tajuddin 
et al. 2013); toenail cadmium was not associ-
ated with LINE-1 methylation in this study 
population. In populations exposed to high 
arsenic levels in drinking water in West Bengal 
and Bangladesh, increasing arsenic exposure 
levels were associated with increasing global 
DNA methylation in peripheral blood cells 
(Majumdar et al. 2010; Pilsner et al. 2007). 
The association of maternal urinary arsenic 
and global methyla tion as measured in Alu and 
LINE-1 repetitive elements and in the LUMA 
assay in cord blood DNA was positive among 
male newborns (n = 58) but inverse among 
female newborns (n = 43) from Bangladesh 
(Pilsner et al. 2012). At low to moderate levels 
of arsenic exposure, increasing arsenic levels in 
toenails have been associated with methylation 
changes in repetitive elements (increasing Alu 
and decreasing LINE-1 DNA methylation) 
in 581 elderly men from the United States 
(Lambrou et al. 2012). In visit 3 data, after 
adjustment for cell hetero geneity, higher 
arsenic exposure levels were significantly associ-
ated with decreased global DNA methylation. 
Random sampling variability and differences 
in residual confounding, study designs, and 
population exposure levels may underlie 
inconsistencies across studies evaluating metal-
related global methylation.
Arsenic exposure has been associated with 
both hyper methylation and hypo methylation 
of gene-specific promoter, with a trend 
toward hyper methylation (Gribble et al. 
Table 2. Cross‑sectional associations [OR (95% CI)] of global DNA methylation (%5‑mC) and global DNA 




Model 1 Model 2 Model 1 Model 2
Age (years)
< 54 24 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
≥ 54 24 0.79 (0.48, 1.30) 0.78 (0.46, 1.32) 0.76 (0.46, 1.26) 0.90 (0.54, 1.50)
Sex
Male 15 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Female 33 1.37 (0.80, 2.33) 1.36 (0.77, 2.38) 1.20 (0.69, 2.07) 1.23 (0.72, 2.10)
Education (years)
≥ 12 29 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
< 12 19 1.23 (0.74, 2.05) 1.18 (0.67, 2.08) 0.64 (0.39, 1.07) 0.74 (0.43, 1.26)
BMI (kg/m2) 
< 30 20 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
≥ 30 27 1.35 (0.81, 2.25) 1.35 (0.80, 2.28) 1.20 (0.73, 1.98) 1.17 (0.71, 1.95)
Waist circumference (cm)
< Sex-specific mediana 20 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
≥ Sex-specific median 26 0.90 (0.53, 1.53) 0.88 (0.52, 1.50) 1.05 (0.63, 1.75) 0.99 (0.59, 1.65)
Percent body fat
< Sex-specific medianb 23 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
≥ Sex-specific median 24 0.94 (0.56, 1.56) 0.90 (0.53, 1.51) 1.47 (0.91, 2.38) 1.58 (0.98, 2.56)
Smoking
Never 20 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Ever 28 0.81 (0.49, 1.35) 0.81 (0.47, 1.38) 1.02 (0.61, 1.72) 1.09 (0.65, 1.82)
Alcohol status
Never 8 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Ever 40 0.97 (0.49, 1.90) 1.06 (0.46, 2.43) 0.85 (0.43, 1.68) 0.71 (0.32, 1.58)
Urinary arsenic (μg/g)c 
< 7.2 24 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
≥ 14.0 24 1.05 (0.64, 1.74) 1.05 (0.61, 1.80) 0.74 (0.44, 1.22) 0.73 (0.44, 1.22)
%iAs
< 8.5 23 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
≥ 8.5 23 0.85 (0.51, 1.43) 0.78 (0.44, 1.39) 0.56 (0.34, 0.92) 0.61 (0.36, 1.01)
%MMA
< 14.4 23 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
≥ 14.4 23 0.73 (0.44, 1.21) 0.78 (0.44, 1.40) 0.59 (0.36, 0.97) 0.71 (0.42, 1.20)
%DMA
< 78.3 23 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
≥ 78.3 23 1.56 (0.95, 2.57) 1.64 (0.93, 2.88) 1.76 (1.07, 2.88) 1.59 (0.95, 2.66)
Cadmium (μg/g)
< 0.87 24 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
≥ 0.87 24 1.64 (1.02, 2.65) 1.75 (0.96, 3.20) 1.16 (0.70, 1.94) 1.08 (0.59, 1.97)
Antimony (μg/g)
< 0.27 24 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
≥ 0.27 24 1.37 (0.84, 2.24) 1.24 (0.71, 2.15) 1.07 (0.64, 1.78) 1.08 (0.64, 1.85)
Tungsten (μg/g)
< 0.13 24 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
≥ 0.13 24 1.50 (0.92, 2.45) 1.46 (0.85, 2.52) 1.25 (0.76, 2.08) 1.13 (0.66, 1.92)
%5-mC 
< 0.32 24 NA NA 1.00 (Ref) 1.00 (Ref)
≥ 0.32 24 NA NA 1.36 (0.82, 2.25) 1.56 (0.95, 2.56)
%5-hmC 
< 0.12 23 1.00 (Ref) 1.00 (Ref) NA NA
≥ 0.12 25 1.63 (1.01, 2.64) 1.93 (1.15, 3.26) NA NA
Abbreviations: NA, not available; Ref, referent. Model 1 was unadjusted; model 2 was adjusted for age (years), sex, 
smoking status (never, former, current), and BMI (kg/m2). 
aSex‑specific medians for waist circumference were 130 cm in men and 130 cm in women. bSex‑specific medians for 
percent body fat were 29.8% in men and 41.40% in women. cSum of inorganic and methylated arsenic species in urine.
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2014; Hossain et al. 2012; Kile et al. 2012; 
Koestler et al. 2013). In 202 Argentinean 
women, urinary arsenic concentrations were 
positively associated with methyla tion of p16 
and MLH1 genes (Hossain et al. 2012). CpG 
sites in gene p16 were also positively asso-
ciated with arsenic exposure in 113 women 
from Bangladesh (Kile et al. 2012). In a 
genome-wide study of DNA methylation in 
cord blood samples from 134 infants, 75% 
of the 44 top statistically significant arsenic-
associated CpG islands showed increased 
methylation with increased arsenic exposure 
levels (Koestler et al. 2013). A hypo-
methylated region in the AS3MT promoter 
was associated with higher arsenic exposure 
in our study population (Gribble et al. 2014). 
Large-sample-size epidemiologic studies are 
needed to evaluate the relationship of metal 
exposures with global DNA and gene-specific 
methyla tion and hydroxymethyla tion in 
human populations.
Arsenic metabolism in humans is usually 
studied as the relative amount of inorganic 
and methylated arsenic metabolites in urine 
(Vahter 2000). Differences in arsenic methyla-
tion patterns in urine (higher %iAs and 
%MMA and lower %DMA) have been associ-
ated with a higher risk of skin lesions, cancer, 
and cardio vascular disease in populations 
Table 3. Prospective associations [OR (95% CI)] of global DNA methylation (%5‑mC) and global DNA hydroxymethylation (%5‑hmC) in 1993–1995 (visit 3) by 
participant characteristics in the Strong Heart Study (SHS).
Characteristic n
Methylation Hydroxymethylation
Model 1 Model 2 Model 3 Model 1 Model 2 Model 3
Age (years)
< 54 21 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
≥ 54 23 0.62 (0.34, 1.10) 0.62 (0.35, 1.12) 0.56 (0.31, 1.03) 0.63 (0.38, 1.10) 0.63 (0.38, 1.05) 0.64 (0.37, 1.10)
Sex
Male 15 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Female 29 0.76 (0.41, 1.42) 0.80 (0.42, 1.53) 0.69 (0.36, 1.33) 1.20 (0.70, 2.08) 1.24 (0.70, 2.18) 1.16 (0.66, 2.04)
Education (years)
≥ 12 27 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
< 12 17 1.08 (0.58, 1.99) 1.06 (0.56, 2.01) 1.07 (0.54, 2.09) 1.20 (0.71, 2.05) 1.17 (0.67, 2.04) 1.23 (0.69, 2.19)
BMI (kg/m2)
< 30 18 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
≥ 30 25 1.67 (0.92, 3.05) 1.69 (0.91, 3.14) 1.69 (0.92, 3.10) 1.05 (0.61, 1.80) 1.08 (0.62, 1.89) 1.01 (0.59, 1.73)
Waist circumference (cm)
< Sex-specific mediana 19 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
≥ Sex-specific median 24 1.19 (0.64, 2.20) 1.16 (0.63, 2.17) 1.16 (0.63, 2.14) 0.86 (0.51, 1.47) 0.85 (0.50, 1.47) 0.82 (0.49, 1.38)
Percent body fat
< Sex-specific medianb 21 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
≥ Sex-specific median 22 1.61 (0.89, 2.92) 1.60 (0.87, 2.93) 1.45 (0.79, 2.65) 1.48 (0.88, 2.49) 1.50 (0.89, 2.55) 1.41 (0.84, 2.36)
Smoking
Never 19 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Ever 25 0.58 (0.32, 1.03) 0.61 (0.33, 1.13) 0.51 (0.27, 0.98) 0.69 (0.41, 1.16) 0.71 (0.41, 1.24) 0.68 (0.39, 1.18)
Alcohol status
Never 8 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Ever 36 0.86 (0.40, 1.87) 0.84 (0.38, 1.85) 0.93 (0.35, 2.44) 0.89 (0.45, 1.75) 0.89 (0.45, 1.78) 0.90 (0.39, 2.07)
Urinary arsenic (μg/g)c 
< 7.2 23 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
≥ 14.0 21 0.58 (0.33, 1.03) 0.54 (0.30, 0.97) 0.59 (0.32, 1.10) 0.78 (0.46, 1.30) 0.73 (0.43, 1.25) 0.80 (0.46, 1.39)
%iAs
< 8.5 21 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
≥ 8.5 22 0.91 (0.50, 1.68) 0.90 (0.48, 1.67) 0.78 (0.40, 1.50) 0.83 (0.49, 1.40) 0.79 (0.46, 1.37) 0.71 (0.40, 1.25)
%MMA
< 14.4 21 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
≥ 14.4 22 0.73 (0.40, 1.34) 0.73 (0.40, 1.34) 0.70 (0.36, 1.37) 0.58 (0.35, 0.96) 0.58 (0.35, 0.98) 0.62 (0.35, 1.10)
%DMA
< 78.3 22 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
≥ 78.3 21 1.57 (0.87, 2.85) 1.61 (0.88, 2.94) 1.75 (0.92, 3.32) 1.34 (0.79, 2.26) 1.38 (0.81, 2.36) 1.32 (0.75, 2.35)
Cadmium (μg/g)
< 0.87 24 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
≥ 0.87 20 0.86 (0.47, 1.56) 0.90 (0.49, 1.66) 1.03 (0.50, 2.11) 1.04 (0.62, 1.76) 1.07 (0.62, 1.83) 0.97 (0.52, 1.80)
Antimony (μg/g)
< 0.27 22 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
≥ 0.27 22 1.71 (0.96, 3.04) 1.93 (1.07, 3.47) 2.15 (1.15, 4.01) 1.15 (0.69, 1.94) 1.22 (0.71, 2.10) 1.16 (0.65, 2.07)
Tungsten (μg/g)
< 0.13 23 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
≥ 0.13 21 0.84 (0.46, 1.52) 0.90 (0.47, 1.71) 0.93 (0.46, 1.86) 1.25 (0.75, 2.10) 1.40 (0.81, 2.44) 1.32 (0.73, 2.37)
%5-mC 
< 0.32 22 NA NA NA 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
≥ 0.32 22 NA NA NA 1.24 (0.74, 2.08) 1.21 (0.71, 2.06) 1.15 (0.67, 1.96)
%5-hmC 
< 0.12 20 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) NA NA NA
≥ 0.12 24 1.23 (0.68, 2.24) 1.16 (0.63, 2.16) 1.28 (0.67, 2.45) NA NA NA
Abbreviations: NA, not available; Ref, referent. Model 1 was unadjusted; model 2 was adjusted for log‑transformed total count of white blood cells and percent of neutrophils; and 
model 3 was adjusted as for model 2 and also adjusted for age (years), sex, smoking status (never, former, current), and BMI (kg/m2). 
aSex‑specific medians for waist circumference were 130 cm in men and 130 cm in women. bSex‑specific medians for percent body fat were 29.8% in men and 41.40% in women. cSum 
of inorganic and methylated arsenic species in urine. 
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exposed to arsenic in drinking water (Chen 
et al. 2003; Del Razo et al. 1997; Hsueh 
et al. 1997; Kile et al. 2011; Steinmaus et al. 
2006; Wu et al. 2006; Yu et al. 2000). In a 
small study population from Mexico (n = 16), 
arsenic species were associated with gene-
specific promoter methylation in 812 genes 
(Bailey et al. 2013). In that study, increasing 
absolute levels of iAs and MMA were mostly 
associated with decreasing levels of promoters’ 
DNA methylation, whereas increasing levels 
of DMA were inconsistently associated with 
both increasing and decreasing methylation 
of specific promoters (Bailey et al. 2013). 
The interpretation of these findings is unclear 
because absolute levels of arsenic metabo-
lites depend not only on arsenic metabo-
lism capability but also on arsenic exposure 
levels. The association of arsenic metabolism 
and global DNA methylation—measured as 
%iAs, %MMA, and %DMA—has seldom 
been explored. In the present study, the 
relation ships of global DNA methylation 
and global DNA hydroxymethyla tion with 
%iAs, %MMA, and %DMA were consis-
tent in the cross-sectional and prospective 
analyses. Individuals with higher %DMA 
(faster methylators of inorganic arsenic) also 
had higher global DNA methyla tion and 
global DNA hydroxy methylation, whereas 
those with higher %iAs and %MMA 
(slower methylators) tended to have lower 
global DNA methylation and global DNA 
hydroxymethylation.
Both DNA methylation and arsenic 
metabolism require S-adenosylmethionine 
(SAM) as the methyl donor. Competitive 
demand between arsenic metabolism and 
DNA methylation for SAM could affect DNA 
methylation status throughout the genome 
(Lee et al. 2009). It is also possible that the 
arsenic methylation profile reflects general 
methylation capability in the body or that 
common enzymes are involved in both arsenic 
and DNA methylation processes. In a recent 
genome-wide linkage scan on arsenic metabo-
lism in our study population (Tellez-Plaza 
et al. 2013), we found suggestive peaks near 
genes encoding several methyl transferases, 
including the genes PRDM9 (PR domain 
zinc finger protein 9, a protein with histone 
methyl transferase activity) and EHMT1 
(histone methyltransferase). Other minor, 
borderline-suggestive peaks were near the 
genes AS3MT (arsenic (III) methyltransferase), 
METTL20 (methyl transferase-like 20), and 
RNMT (RNA methyltransferase). In a study 
of 103 Argentinean women and 127 women 
from Bangladesh delivering singleton infants, 
AS3MT haplo types associated with efficient 
arsenic metabolism were also associated with 
DNA methylation and gene expression of 
AS3MT and other genes on chromosome 10 
(Engstrom et al. 2013). In that study, which 
assayed DNA methylation on a genome-wide 
basis by using a microarray technology, the 
association of AS3MT efficiency and arsenic 
metabolism and DNA methylation status in 
other chromosomes and genomic regions was 
not reported.
Evidence for plausible mechanisms 
for effects of metals other than the connec-
tion between arsenic and DNA-methylation 
metabolism on DNA methylation is relatively 
scarce. Experimental ex vivo evidence using 
M.SssI DNMT (a bacterial DNMT that 
recognizes the same sequence as mammalian 
DNMTs) showed that cadmium exposure 
was an effective, non competitive inhibitor of 
DNMT (Takiguchi et al. 2003). In rat liver 
cells, short-term cadmium exposure induced 
DNA global hypomethylation; however, 
prolonged exposure resulted in global DNA 
hyper methylation (Takiguchi et al. 2003). 
Results of other studies are consistent with 
these findings (Benbrahim-Tallaa et al. 
2007; Jiang et al. 2008; Poirier and Vlasova 
2002). Metals could indirectly impair both 
one-carbon (Lee et al. 2009) and citric acid 
metabolic (Chia et al. 2011) pathways. There is 
evidence suggesting that TETs are regulated by 
redox reaction (Dao et al. 2014). TET proteins 
were activated in the presence of high oxygen 
levels and alpha-ketoglutarate (α-KG), which 
is generated in citric acid cycle (Chowdhury 
et al. 2011; Xu et al. 2011). It has been 
suggested that imbalance of redox reaction 
in cells in response to environ mental stress 
or toxicants may affect the ratio of oxidants 
and eventually alter production of α-KG and 
activation of TETs (Chia et al. 2011; Dao 
et al. 2014). Whether metal exposure–induced 
oxidative stress (Prozialeck et al. 2008; Valko 
et al. 2005) affects TET-mediated hydroxy-
methylation is still unknown. It is also possible 
that, in addition to cadmium, other divalent 
metals can inhibit DNMT and other enzymes 
involved not only in one-carbon metabolism 
and citric acid metabolism pathways but also 
in histone acetylation, deacetylation, and 
methylation pathways (Chervona and Costa 
2012; Dai and Wang 2014). More mechanistic 
research is needed for evaluating the role of 
metals in inducing DNA-methylation changes.
The major limitation of the present study 
is the small sample size. Another limita-
tion is the tissue-dependent nature of DNA 
methylation and DNA hydroxy methylation 
changes. We measured global methylation 
and global hydroxymethylation in blood cell 
DNA, which is composed of different cell 
types, each with a different DNA methyla tion 
profile. Information on blood cell counts was 
available only for visit 3. Thus, for visit 3 we 
could incorporate information on cell hetero-
geneity in the analysis, which showed largely 
consistent and somewhat stronger associa-
tions (Table 3, model 2). DNA methyla tion 
markers measured in blood samples, 
moreover, have been related to immuno-
logic disease, mental disease, cardio vascular 
disease, and cancer, suggesting that blood 
cells can be an adequate tissue for conducting 
epi genetic studies in epidemiologic samples 
(Terry et al. 2011). Finally, creatinine may 
be a surrogate for several key mediators of the 
DNA methyla tion and arsenic metabo lism 
processes because DNA methylation, arsenic 
methyla tion (Lee et al. 2009; Loenen 2006), 
and creatine synthesis (Brosnan et al. 2011) 
use SAM as the methyl donor. Creatinine, a 
break-down product of creatine phosphate 
in muscle, is generally produced at a constant 
rate depending on muscle mass (Heymsfield 
et al. 1983). Experimental models are needed 
to evaluate whether the connection between 
DNA methylation and arsenic metabolism 
and measures of body composition are related 
to muscle mass.
The strengths of the present study include 
the availability of information in several poten-
tial determinants of global DNA methyla tion 
and hydroxymethylation, including metals 
and arsenic metabolism and the high quality 
of standardized protocols for the recruitment 
of participants, conduction of interviews, 
physical examinations, collection of biological 
samples, and laboratory analysis. Importantly, 
American Indian populations are an important 
ethnic group that has often been under studied. 
Findings from American Indian popula-
tions have proven to be applicable to other 
groups with high rates of diabetes mellitus 
and obesity (Fretts AM et al. 2012; Howard 
et al. 1999; Xu et al. 2012). Our findings 
can thus be relevant to many populations in 
the United States and around the world who 
are increasingly affected by the obesity and 
diabetes epidemics. Finally, in addition to 
evaluating determinants of traditional global 
DNA methylation, we also evaluated deter-
minants of global DNA hydroxymethylation, 
which is a novel and relatively unknown 
epigenetic marker.
Conclusions
We found a positive correlation between 
global DNA methylation and global DNA 
hydroxymethylation in human blood samples 
collected in the same individuals at two time 
points, with confirmation of findings in an 
independent population with a low burden 
of disease, supporting that both epigenetic 
measures are related at the population level. 
The consistency in the trend of the associa-
tions between these epigenetic modifications 
and categories of available determinants, 
especially arsenic exposure and metabolism, 
suggests the need for understanding which 
of the two measures is a better biomarker for 
environmental epigenetic effects in future 
large-scale epidemiologic studies.
DNA global methylation and hydroxymethylation
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